Division of Endocrinology, Veterans Affairs Medical Center, and Department of Medicine, University of California, San Francisco, San Francisco, CA 94121, USA.
Bone. 2012 Mar;50(3):628-37. doi: 10.1016/j.bone.2011.11.010. Epub 2011 Nov 30.
We examined age-related changes in biochemical markers and regulators of osteoblast and osteoclast activity in C57BL/6 mice to assess their utility in explaining age-related changes in bone. Several recently discovered regulators of osteoclasts and osteoblasts were also measured to assess concordance between their systemic levels versus their levels in marrow plasma, to which bone cells are directly exposed. MicroCT of 6-, 12-, and 24-month-old mice indicated an early age-related loss of trabecular bone volume and surface, followed by endocortical bone loss and periosteal expansion. Trabecular bone loss temporally correlated with reductions in biomarkers of bone formation and resorption in both peripheral blood and bone marrow. Endocortical bone loss and periosteal bone gain were not reflected in these protein biomarkers, but were well correlated with increased expression of osteocalcin, rank, tracp5b, and cathepsinK in RNA extracted from cortical bone. While age-related changes in bone turnover markers remained concordant in blood versus marrow, aging led to divergent changes in blood versus marrow for the bone cell regulators RANKL, OPG, sclerostin, DKK1, and serotonin. Bone expression of runx2 and osterix increased progressively with aging and was associated with an increase in the number of osteoprogenitors and osteoclast precursors. In summary, levels of biochemical markers of bone turnover in blood and bone marrow plasma were predictive of an age-related loss of trabecular surfaces in adult C57BL/6 mice, but did not predict gains in cortical surfaces resulting from cortical expansion. Unlike these turnover markers, a panel of bone cell regulatory proteins exhibited divergent age-related changes in marrow versus peripheral blood, suggesting that their circulating levels may not reflect local levels to which osteoclasts and osteoblasts are directly exposed.
我们研究了 C57BL/6 小鼠中成骨细胞和破骨细胞活性的生化标志物和调节剂的年龄相关性变化,以评估它们在解释骨衰老相关变化中的作用。还测量了几种新发现的破骨细胞和成骨细胞调节剂,以评估其系统水平与骨髓血浆水平(骨细胞直接暴露于此)之间的一致性。6、12 和 24 月龄小鼠的 microCT 表明,早期与年龄相关的骨小梁体积和表面丢失,随后是皮质内骨丢失和骨膜扩张。骨小梁丢失与外周血和骨髓中骨形成和吸收生物标志物的减少在时间上相关。皮质内骨丢失和骨膜骨增加并没有反映在这些蛋白质生物标志物中,但与从皮质骨中提取的 RNA 中骨钙素、rank、tracp5b 和组织蛋白酶 K 的表达增加密切相关。虽然骨转换标志物的年龄相关性变化在血液与骨髓之间仍然一致,但随着年龄的增长,血液与骨髓之间的骨细胞调节剂 RANKL、OPG、sclerostin、DKK1 和 5-羟色胺的变化出现分歧。Runx2 和osterix 的骨表达随年龄逐渐增加,并与成骨细胞前体和破骨细胞前体数量的增加相关。总之,血液和骨髓血浆中骨转换生化标志物的水平可预测成年 C57BL/6 小鼠与年龄相关的小梁表面丢失,但不能预测由于皮质扩张而导致的皮质表面增加。与这些转换标志物不同,一组骨细胞调节蛋白在骨髓与外周血之间表现出不同的年龄相关性变化,表明其循环水平可能不能反映破骨细胞和成骨细胞直接暴露的局部水平。